Journal of Veterinary Clinics (한국임상수의학회지)

The Korean Society of Veterinary Clinics (한국임상수의학회)
권호 표지
DOI QR코드

DOI QR Code

Long-Term Follow Up of Refractory Myotonia Associated with Hyperadrenocorticism in a Maltese Dog

  • Nam, Sookin (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University) ;
  • Kang, Byeong-Teck (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungbuk National University) ;
  • Song, Kun-ho (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University) ;
  • Seo, Kyoung-won (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University)
  • Received : 2020.07.20
  • Accepted : 2020.10.07
  • Published : 2020.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

A 12-year-old, female Maltese was referred with uncontrolled hyperadrenocorticism (HAC). Despite well management of HAC through treatment with trilostane and serial monitoring with ACTH stimulation tests for over three years, stiffness of the neck and limbs progressively worsened over time. Neurological test was performed, which showed no abnormalities of cranial nerves. Proprioception was delayed but the cause appeared to be due to stiffness of limb muscles. Muscle tone had increased over time and stiffness had worsened to the extent where it made walking difficult. MRI scans showed no orthopedic or spinal diseases, and pituitary microadenoma was confirmed with pituitary gland measurement of 6 × 6.4 × 4.5 mm (H × W × L). Electromyography presented random discharges with fluctuating amplitude and frequency, which were consistent with myotonic discharges. There were no improvements of myotonic signs despite treatment for HAC with trilostane. Supplementation of L-carnitine and coenzyme Q-10 to mitigate muscle stiffness, following diazepam and methocarbamol to help with muscle rigidity, failed to show any positive effect and the dog died a sudden death, 1,182 days after the initial visit.

Keywords

References

  1. Barker E, Campbell S, Tebb A, Neiger R, Herrtage M, Reid S, Ramsey I. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005; 19: 810-815. https://doi.org/10.1111/j.1939-1676.2005.tb02769.x
  2. Bell R, Neiger R, McGrotty Y, Ramsey I. Study of the effects of once daily doses of trilostane on cortisol concentrations and responsiveness to adrenocorticotrophic hormone in hyperadrenocorticoid dogs. Vet Rec 2006; 159: 277-281. https://doi.org/10.1136/vr.159.9.277
  3. Boretti F, Musella C, Burkhardt W, Kuemmerle-Fraune C, Riond B, Reusch C, Sieber-Ruckstuhl N. Comparison of two prepill cortisol concentrations in dogs with hypercortisolism treated with trilostane. BMC Vet Res 2018; 14(1): 417. https://doi.org/10.1186/s12917-018-1750-3
  4. Braddock J, Church D, Robertson I, Watson A. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. Aust Vet J 2003; 81: 600-607. https://doi.org/10.1111/j.1751-0813.2003.tb12498.x
  5. Cook A, Bond K. Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism. J Am Vet Med Assoc 2010; 237: 801-805. https://doi.org/10.2460/javma.237.7.801
  6. Ettinger S, Feldman E, Cote, E. Textbook of Veterinary Internal Medicine. St. Louis, Missouri: Elsevier. 2017: 1799, 1807.
  7. Feldman E, Nelson R, Reusch C, Scott-Moncrieff J, Behrend E. Canine & Feline Endocrinology. 4th ed. St. Louis, Missouri: Elsevier. 2015: 434.
  8. Fracassi F, Corradini S, Floriano D, Boari A, Aste G, Pietra M, Bergamini P, Dondi F. Progno sticf actors for survival in dogs with pituitary-dependent hypercortisolism treated with trilostane. Vet Rec 2014; 176: 49-49. https://doi.org/10.1136/vr.102546
  9. Greene CE, Lorenz MD, Munnell JF, Prasse KW, White NA, Bowen JM. Myopathy associated with hyperadrenocorticism in the dog. J Am Vet Med Assoc 1979; 174: 1310-1315.
  10. Imbe A, Tanimoto K, Inaba Y, Sakai S, Shishikura K, Imbe H, Hanafusa, T. Effects of L-carnitine supplementation on the quality of life in diabetic patients with muscle cramps. Endocr J 2018; 65: 521-526. https://doi.org/10.1507/endocrj.EJ17-0431
  11. Macfarlane L, Parkin T, Ramsey I. Pre-trilostane and threehour post-trilostane cortisol to monitor trilostane therapy in dogs. Vet Rec 2016; 179: 597-597. https://doi.org/10.1136/vr.103744
  12. McKerrell RE. Myotonia in Man and Animals: Confusing Comparisons. Equine Vet J 1987; 19: 266-267. https://doi.org/10.1111/j.2042-3306.1987.tb01401.x
  13. Nagata N, Yuki M. Long-term outcome of myotonia associated with hyperadrenocorticism in 2 dogs. Can Vet J 2015; 56: 931-933.
  14. Neiger R, Hurley K, Ramsey I, O'Connor J, Mooney C. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2002; 150: 799-804. https://doi.org/10.1136/vr.150.26.799
  15. Nelson R. Small Animal Internal Medicine. 6th ed: Elsevier - Health Science. 2019: 872.
  16. Platt SR, Olby NJ, Small B. BSAVA Manual of Canine and Feline Neurology. Cheltenham: British Small Animal Veterinary Association. 2013: 8, 23, 62.
  17. Swinney G, Foster S, Chruch D, Malik R. Myotonia associated with hyper-adrenocorticism in two dogs. Aust Vet J 1998; 76: 722-724. https://doi.org/10.1111/j.1751-0813.1998.tb12299.x
  18. Vaughan M, Feldman E, Hoar B, Nelson R. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc 2008; 232: 1321-1328. https://doi.org/10.2460/javma.232.9.1321
  19. Wenger M, Sieber-Ruckstuhl NS, Muller C, Reusch CE. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism. Am J Vet Res 2004; 65: 1245-1250. https://doi.org/10.2460/ajvr.2004.65.1245